金吾财讯 | 康希诺生物(06185)公告，于2024年度，录得归属于母公司所有者的净亏损3.79亿元（人民币，下同），去年同期录得净亏损14.83亿元，同比大幅收窄74.45%；归属于母公司所有者的扣除非经常性损益的净亏损4.41亿元，同比大幅收窄72.61%。基本每股亏损1.53元。
上述变动主要系：集团持续优化资源配置、推进降本增效措施，经营效率显着提升，报告期内管理费用、研发费用较去年同期大幅下降，资产减值损失也同比大幅减少，故亏损显着收窄。
期内，总营收8.46亿元，同比增长137.01%。变动主要系：MCV4作为中国市场上唯一的四价流脑结合疫苗，集团通过对其市场的精准布局推动持续放量，产品渗透率不断提升，实现销量快速增长；同时，集团经营受全球公共卫生事件的影响已经基本消除。因此，集团营业收入较去年同期大幅增长。
期内，集团工作重点主要为推进流脑结合疫苗的商业化进程及非新冠疫苗产品的研发。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.